Exact Sciences Corporation (FRA:EXK)
Germany · Delayed Price · Currency is EUR | Market Cap | 16.35B +69.8% |
| Revenue (ttm) | 2.63B +14.5% |
| Net Income | -840.86M |
| EPS | -4.49 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 119.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 5 |
| Open | 85.09 |
| Previous Close | 85.07 |
| Day's Range | 85.09 - 85.09 |
| 52-Week Range | 33.80 - 88.16 |
| Beta | n/a |
| RSI | 45.60 |
| Earnings Date | Feb 17, 2026 |
About Exact Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri... [Read more]
Financial Performance
In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.
Financial numbers in USD Financial StatementsNews
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were ...
Alger Small Cap Growth Fund Q4 2025 Portfolio Update
Class A shares of the Alger Small Cap Growth Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were...
Alger Mid Cap Focus Fund Q4 2025 Portfolio Update
Exact Sciences Corporation, Natera, Inc., and Guardant Health, Inc. were among the top contributors to performance. Roblox Corp., Robinhood Markets, Inc., and Nebius Group were among the top detractor...
Park Capital Management, LLC / WI Buys 2,305 Shares of Exact Sciences Corp (EXAS)
Park Capital Management, LLC / WI Buys 2,305 Shares of Exact Sciences Corp (EXAS)
HARBOR CAPITAL ADVISORS, INC. Sells 18,705 Shares of Exact Sciences Corp (EXAS)
HARBOR CAPITAL ADVISORS, INC. Sells 18,705 Shares of Exact Sciences Corp (EXAS)
Exact Sciences (EXAS) Downgraded by Mizuho, Price Target Raised to $105 | EXAS Stock News
Exact Sciences (EXAS) Downgraded by Mizuho, Price Target Raised to $105 | EXAS Stock News
Essex LLC Buys 2,900 Shares of Exact Sciences Corp (EXAS)
Essex LLC Buys 2,900 Shares of Exact Sciences Corp (EXAS)
Exact Sciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Exact Sciences: Abbott Acquisition A Positive Sign For Oncology Diagnostics
EXAS Stock Rating Downgraded to 'In-Line' by Evercore ISI Group | EXAS Stock News
EXAS Stock Rating Downgraded to 'In-Line' by Evercore ISI Group | EXAS Stock News
Top 2 Health Care Stocks That May Crash In Q1
As of Jan. 2, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS)....
Should You Continue to Hold EXAS Stock in Your Portfolio Now?
Exact Sciences is investing heavily in R&D and commercial capabilities to boost Cologuard adoption, but competition and macro pressures cloud the outlook.
EXAS Quantitative Stock Analysis
Below is Validea's guru fundamental report for EXACT SCIENCES CORP (EXAS). Of the 22 guru strategies we follow, EXAS rates highest using our P/B Growth Investor model based on the published strategy o...
XBI, EXAS, RVMD, RNA: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approxima...
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect MRD Test in Early Triple-Negative Breast Cancer at SABCS
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect molecular residual disease (MRD) ...
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® ...
XBI, EXAS, RVMD, RNA: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approxima...
Validea Detailed Fundamental Analysis - EXAS
Below is Validea's guru fundamental report for EXACT SCIENCES CORP (EXAS). Of the 22 guru strategies we follow, EXAS rates highest using our P/B Growth Investor model based on the published strategy o...
Noteworthy ETF Inflows: XBI, EXAS, RVMD, RNA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approxima...
Top 2 Health Care Stocks You May Want To Dump This Month
As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
$100 Invested In Exact Sciences 15 Years Ago Would Be Worth This Much Today
Exact Sciences (NASDAQ: EXAS) has outperformed the market over the past 15 years by 9.5% on an annualized basis producing an average annual return of 21.58%. Currently, Exact Sciences has a market ca...
Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 15 Years
Exact Sciences (NASDAQ: EXAS) has outperformed the market over the past 15 years by 8.51% on an annualized basis producing an average annual return of 20.65%. Currently, Exact Sciences has a market c...
EXAS Quantitative Stock Analysis
Below is Validea's guru fundamental report for EXACT SCIENCES CORP (EXAS). Of the 22 guru strategies we follow, EXAS rates highest using our P/B Growth Investor model based on the published strategy o...
This Coinbase Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...